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Detection of functional protein 
domains by unbiased genome-wide 
forward genetic screening
Mareike Herzog1, Fabio Puddu1, Julia Coates1, Nicola Geisler1, Josep V. Forment1,2 &  
Stephen P. Jackson1
Establishing genetic and chemo-genetic interactions has played key roles in elucidating mechanisms by 
which certain chemicals perturb cellular functions. In contrast to gene disruption/depletion strategies 
to identify mechanisms of drug resistance, searching for point-mutational genetic suppressors that 
can identify separation- or gain-of-function mutations has been limited. Here, by demonstrating its 
utility in identifying chemical-genetic suppressors of sensitivity to the DNA topoisomerase I poison 
camptothecin or the poly(ADP-ribose) polymerase inhibitor olaparib, we detail an approach allowing 
systematic, large-scale detection of spontaneous or chemically-induced suppressor mutations in yeast 
or haploid mammalian cells in a short timeframe, and with potential applications in other haploid 
systems. In addition to applications in molecular biology research, this protocol can be used to identify 
drug targets and predict drug-resistance mechanisms. Mapping suppressor mutations on the primary 
or tertiary structures of protein suppressor hits provides insights into functionally relevant protein 
domains. Importantly, we show that olaparib resistance is linked to missense mutations in the DNA 
binding regions of PARP1, but not in its catalytic domain. This provides experimental support to the 
concept of PARP1 trapping on DNA as the prime source of toxicity to PARP inhibitors, and points to a 
novel olaparib resistance mechanism with potential therapeutic implications.
In model organisms, genetic screens have long been used to characterize gene functions, to define gene networks, 
and to identify the mechanism-of-action of drugs1–4. The genetic relationships identified by such screens have 
been shown to involve positive and negative feedbacks, backups and cross-talks that would have been extremely 
difficult to discover using other approaches5. Currently, the large majority of reported screens in model organ-
isms and in mammalian-cell systems have used gene-deletion libraries and/or methodologies to inactivate gene 
functions, such as short-interfering RNA, CRISPR-Cas9 or transposon-mediated mutagenesis6,7. While powerful, 
such approaches usually identify loss-of-function phenotypes, and only rarely uncover separation-of-function or 
gain-of-function mutations. Gene overexpression screens have successfully identified gain-of-function alleles, but 
these screens often involve non-physiological protein levels. This limitation is significant because such separation- 
or gain-of-function mutations – which can arise spontaneously or via the action of genotoxic agents – can dra-
matically affect cell functions or cellular response to chemicals, and can have profound impacts on human health 
and disease8,9. Suppressor screens, either based on lethal genetic deficiencies and/or the use of drugs, have also 
facilitated the characterization of functionally relevant protein domains and sites of post-translational protein 
modification through the identification of relevant single nucleotide DNA variants (SNV)s10.
In their simplest experimental setup, suppressor screens based on point-mutagenesis rely on four tools: 
(i) a genetically amenable organism or cell; (ii) a selectable phenotype; (iii) a method to create a library of 
mutants; and (iv) a method to identify mutations driving the suppressor phenotype amongst all the mutations 
in the library. Reflecting their relative amenability, these screens have mostly been carried out in microorgan-
isms, either bacteria or yeasts, both of which benefit from the ability to survive in a stable haploid state. Despite 
not being strictly essential for such studies, a haploid state facilitates the identification of loss-of-function or 
separation-of-function recessive alleles, which would be masked in a heterozygous diploid cell state11. While 
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the first three tools mentioned above are often amenable to a researcher, the lack of fast and efficient methods to 
bridge the knowledge-gap between phenotype and genotype has discouraged the widespread implementation of 
suppressor screens based on point-mutagenesis. Indeed, until recently, recessive suppressor alleles could only be 
identified by labor-intensive methods involving genetic mapping and cloning in yeast, whereas the natural diploid 
state of mammalian cells largely precluded straightforward SNV suppressor screens in such systems.
Here, we describe an approach to overcome the above limitations that is based on sequencing of genomic 
DNA extracted from various independent suppressor clones, followed by bioinformatic analysis. With small 
adaptations, this method can be applied to both the budding yeast Saccharomyces cerevisiae and other haploid 
model organisms, as well as to haploid mammalian cells (Fig. 1). To highlight the utility of this approach, we 
describe its application to study resistance to the anti-cancer drugs camptothecin or olaparib, leading to the 
identification of various mutations in yeast TOP1 and in mouse Parp1, respectively. Importantly, we establish that 
drug target identification and mechanisms of drug resistance can be unveiled without a priori knowledge of the 
drug target. Furthermore, if a sufficient number of chemical-genetic suppressors is screened, this method also 
allows identification of functional protein domains required to drive drug sensitivity and resistance.
Results
Identification of TOP1 mutations conferring camptothecin resistance. To demonstrate the utility 
of the procedure described above, we sought to identify mutations imparting resistance to camptothecin, a DNA 
topoisomerase 1 inhibitor12–14. To do this, we employed yeast strains carrying mutations inactivating pathways 
required for camptothecin resistance. These specific mutations (rad50S, sae2-F267A, rtt107∆, tof1∆, sae2∆mre11-
H37R-tel1∆) were chosen for their ability to induce camptothecin hypersensitivity15–18. To maximize the variety 
of potential mutations driving drug resistance, two of the five strains used were mutagenized with ethyl methane 
sulfonate (EMS), an alkylating agent that induces SNVs19, before plating them in the presence of camptothecin. In 
all cases, camptothecin-resistant colonies were readily detectable after 2–3 days of growth at 30 °C.
Genomic DNA sequencing of the resistant clones highlighted TOP1 as the gene carrying the largest number of 
unique mutations in our dataset, as expected for it being the drug target. The second most mutated gene — PDR1 
that is known to regulate a pathway of multi-drug resistance20 —carried 11 unique mutations, 10 of which did 
not co-occur with mutations in TOP1, whereas all the mutations found in the third most mutated gene (GLT1) 
co-occurred with mutations in either TOP1 or PDR1, suggesting that GLT1 mutations do not drive camptoth-
ecin resistance per se (Fig. 2a and data not shown). It is possible that the unexpectedly high frequency of GLT1 
mutations could arise from them somehow enhancing cell survival to EMS, as these mutations are only found in 
EMS-mutagenized samples. Globally, out of the 251 yeast strains sequenced, 191 contained one or more mutation 
in TOP1 (Fig. 2b, light yellow). Furthermore, by manual inspection, we found that 27 additional strains carried 
mutations in TOP1 (Fig. 2b, dark yellow); the inability to automatically detect these mutations was caused by 
the fact that these strains were either not pure clones, or they carried large (>25 bp) deletions in TOP1 (Fig. 2b 
and Supplementary Figure S1). To the list of TOP1-mutated camptothecin-resistant strains, we added another 
38 strains bearing TOP1 mutations that we had identified in previous, published screens16,21, bringing the total 
number of TOP1 mutants analyzed to 256.
Figure 1. Experimental workflow for a suppressor screen. The typical workflow of a suppressor screen using 
S. cerevisiae (left) or mouse embryonic stem cells (right) is depicted. Details of differences between the two 
systems are illustrated where appropriate. Variation in mutation numbers for an organism can be due to the 
choice of background strain, mutagenizing agent and other experimental factors.
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Missense, nonsense and frameshift TOP1 mutations were roughly equally represented in the non-mutagenized 
samples. However, where samples had been mutagenized with EMS the vast majority of mutations were nonsense 
or missense base substitutions (Fig. 2c). In the few cases in which the same suppressor clone contained missense 
and nonsense mutations in TOP1, the suppressive effect was attributed to the gained STOP codon.
When the positional distribution of each mutation type was plotted, nonsense and frameshift mutations were 
shown to be quite evenly distributed along the length of the TOP1 open reading frame (Fig. 2d and e). The 
prediction is that such mutations either result in null alleles – as the prematurely-terminated messenger RNA 
(mRNA) would be degraded by nonsense-mediated decay mechanisms22 – or would give rise to an unstable 
protein or a truncated version that could retain partial activity. Since the Y727 residue is essential for the catalytic 
activity of Top1, truncation before this residue is predicted to produce a non-functional protein23,24. As might 
be expected, the distribution of nonsense mutations loosely correlated with them arising from codons in the 
open reading frame that only required one nucleotide change to change them to a STOP codon (Supplementary 
Figure S1). Notably, the observed enrichment of frameshifts near the 5′ end of the TOP1 transcript was local-
ized to an 8-nucleotide homopolymeric adenine tract that is presumably particularly susceptible to mutagenesis 
(Supplementary Figure S1).
In striking contrast to the situation with nonsense or frameshift mutation, missense mutations were localized 
to specific regions of the TOP1 protein-coding sequence, overlapping with known functional domains of Top1. 
Indeed, the vast majority of mutations identified localized within three distinct regions of the larger DNA bind-
ing and catalytic domain, while a minority was located in the smaller C-terminal domain, essential for catalysis 
(Fig. 2f).
Functional consequences of the amino acid residue changes induced by missense mutations were assessed by 
using PROVEAN and PredicProt25,26. These tools use chemical properties of amino acid residues and phyloge-
netic conservation to predict whether or not a particular substitution is likely to be functionally tolerated by the 
protein analyzed. Both these methods suggested that the vast majority of the TOP1 mutations we identified in 
camptothecin resistant strains were likely to produce deleterious effects (PROVEAN score < −2.5; PredictProtein 
score >50) (Fig. 3a). Notably, missense mutations located in the C-terminal domain of Top1 affected both con-
served and non-conserved residues and were primarily positioned in the vicinity of the catalytic residue Y727, 
although three substitutions were closer to the C-terminus of the protein (Fig. 3b).
Figure 2. Screening for camptothecin resistance highlights TOP1 and its functional domains. (a) Genes found 
mutated in screenings for camptothecin resistance sorted by the number of non-synonymous, independent 
mutations identified in each gene. (b) Fraction of strains identified as mutated in TOP1 by initial analysis (light 
yellow) and upon manual inspection of the TOP1 gene (dark yellow); blue represents clones where no TOP1 
mutation was identified. (c) Mutation types identified in EMS mutagenized samples and non-EMS mutagenised 
samples. Location of nonsense (d), frameshift (e) and missense (f) mutations in the TOP1 gene with respect to 
the primary protein sequence. Mutations identified in EMS-treated samples are colored red, while those from 
non-mutagenized samples are colored green.
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Top1 binds to DNA via a clamp-like mechanism in which DNA binding stimulates a conformational change 
in the protein. Thus, opposable “lip” domains encircle the DNA, stabilizing binding through establishing 
non-covalent protein-DNA and lip-lip interactions (Fig. 3c)27,28. Approximately two thirds of the missense sup-
pressor mutations identified in the DNA binding domain clustered within the Lip1 and Lip2 regions, highlight-
ing their importance for Top1 function (Fig. 3d; the Lip2 domain also contains an active-site residue, R420). 
Remaining mutations clustered between amino acid residues 500 and 600, which encompass the end of the DNA 
binding/catalytic domain and the base of the coiled-coil linker domain. In this region two other active site resi-
dues (R517 and H558) are located (Fig. 3d).
Collectively, these results showed that even with no a priori knowledge, our approach for identifying 
drug-resistant strains and associated mutations would have identified Top1 as the likely target of camptothe-
cin and would have highlighted the critical Top1 domains functionally relevant for Top1 activity and drug 
hypersensitivity.
Identification of Parp1 mutations conferring olaparib resistance. Based on a similar approach to 
that described above, we recently identified genes whose mutation in haploid mammalian cells causes resist-
ance to the anti-metabolite drug 6-thioguanine29. To further highlight the wider applicability of our approach in 
mammalian cell systems, we carried out a screen to identify mutations that allow haploid mouse cells to survive 
in the presence of the anti-cancer agent olaparib, a potent poly ADP-ribose polymerase (PARP) small-molecule 
inhibitor30,31. Thus, wild-type, haploid mouse embryonic stem cells (mESCs) were mutagenized by using EMS, 
and mutant libraries were screened for resistance to olaparib (Fig. 1a). Forty-five olaparib-resistant clones were 
isolated and subjected to whole-exome sequencing.
Analysis of ensuing sequence data for putative, acquired mutations, revealed Parp1 as the most mutated gene 
in the dataset with 25 different mutations detected (Fig. 4a, Supplementary Table S3). Globally, 40 out of the 45 
clones harbored Parp1 mutations (Fig. 4b, Supplementary Table S3). Further manual examination of the aligned 
sequencing data from the five remaining clones revealed that four of these also likely carried mutations affecting 
PARP1 (Supplementary Figure S2). Two of those five (A7, B7) likely carry the R138C missense mutation identi-
fied in another clone (Supplementary Figure S2, Fig. 4c), while two other clones (A9, H10) harbored nonsense 
mutations at codon 341 (Supplementary Figure S2). Importantly, mutations in the second and third most mutated 
genes (Ttn and Plch1 with 9 and 5 different mutations, respectively) never occurred in isolation in the absence of 
Parp1 mutations, while Parp1 mutations also occurred in the absence of Ttn or Plch1 mutations. These data thus 
Figure 3. Mutations conferring camptothecin resistance affect key functional residues in TOP1. (a) 
Computational predictions for consequences of TOP1 missense mutations as predicted by PredictProtein 
(y-axis; a score above 50 is considered deleterious) and PROVEAN (x-axis; a score below −2.5 is considered 
deleterious). Datapoints are colored by the domain that the missense mutations occur in: red and orange denote 
mutations falling within the Lip1 and Lip2 domains, respectively, blue represents the catalytic domain before 
the Linker, green the C-terminal catalytic domain. (b) Multi-species alignment of the Top1 protein catalytic 
domain, with the tyrosine residue critical for catalysis (Y727) being highlighted in orange and mutations 
identified in this screen being highlighted in boldface red. (c) Model of the Top1 mode of DNA binding. The 
protein wraps around to double-stranded DNA with its two Lip domains, like a grasping hand. (d) Missense 
mutations identified in the DNA-binding clamp and active site region with respect to the Lip DNA-binding 
regions and the active site. The region critical for DNA binding and catalysis is highlighted in yellow, and 
mutations are represented by blue squares. Below is a depiction of the sequence and loop structure of the Lip1 
and Lip2 regions in yellow, with specific mutations indicated in light blue.
www.nature.com/scientificreports/
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highlighted how such an analysis would have identified PARP1 as the likely prime driver of olaparib sensitivity 
without any knowledge about the drug’s mechanism-of-action (see below for further discussion).
Of the Parp1 mutations we detected, more than half led to premature termination codons, splice acceptor/
donor, or frameshift mutations, which would presumably lead to the production of aberrant mRNAs subject to 
nonsense-mediated decay and/or the generation of unstable, truncated PARP1 protein. As we previously noted 
for premature-termination mutations in yeast TOP1, these mutations did not cluster in any particular domain(s) 
of the Parp1 open reading frame (Fig. 4c). Furthermore, similar to what we observed in yeast, EMS treatment 
resulted in an overrepresentation of single nucleotide variants, compared to frameshift mutations (Fig. 4c).
Strikingly, missense mutations detected in Parp1 were more frequent in the N-terminal part of the protein, 
where the DNA-binding domains reside, while no such mutations were observed in the catalytic domain (Fig. 4c). 
Analysis of PARP1 protein levels indicated that other than G400R and A610V, which resulted in complete loss 
or marked reduction of the PARP1 protein product, no other of the identified missense mutations impacted 
on PARP1 protein stability (Fig. 5a, Supplementary Figure S3). Computational predictions for the likely con-
sequences of these remaining missense mutations on protein structure and function suggested that all of them 
were functionally deleterious (Fig. 4d). Since all these missense mutations localized within domains known to be 
involved in DNA binding, we examined their locations relative to the DNA-protein interface as defined by pre-
viously published PARP1 structures32,33 (Fig. 5b). Notably, most of the missense mutations affecting residues in 
the DNA binding domains clustered at the DNA-protein interface, and did so in proximity to residues that make 
key DNA contacts33.
Without any a priori knowledge about how olaparib causes cell toxicity, the above data would have suggested 
that such toxicity is largely driven by a mechanism connected to PARP1 DNA binding. To test this idea, we 
assessed the missense mutations identified in the DNA binding domains of PARP1 for their potential effects on 
Figure 4. A screen for olaparib resistance indicates critical functional residues in PARP1. (a) Genes found 
mutated in the olaparib resistant clones sorted by the number of non-synonymous, independent mutations 
per gene. (b) Fraction of strains identified by analysis workflow to carry a mutation in Parp1. (c) Locations of 
mutations with respect to the protein sequence. The lower panel shows the distribution of missense mutations, 
while the upper panel contains all mutations likely to lead to a loss of PARP1 protein: nonsense, frameshift and 
splice acceptor/donor nucleotide mutations as well as mutations of the start codon. (d) The likelihood of being 
deleterious of Parp1 missense mutations as predicted by PredictProtein (y-axis; a score above 50 is considered 
deleterious) and PROVEAN (x-axis; a score below −2.5 is considered deleterious). Datapoints are coloured 
by the domain the missense mutations occur in: Light blue, dark blue and green are the three Zinc fingers, 
respectively, purple denotes the BRCT domain, while red indicates the WGR domain.
www.nature.com/scientificreports/
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the ability of PARP1 to bind a double-stranded DNA oligonucleotide. Significantly, this analysis revealed that all 
the point mutants that did not reduce PARP1 levels showed reduced levels of DNA binding when compared to the 
wild-type PARP1 protein (Fig. 5c, Supplementary Figure S3). Consistent with PARP1 DNA binding triggering its 
auto-modification by poly ADP-ribose, we found that the PARP1 S568F mutation, which impairs DNA binding, 
did not exhibit evidence of PARylation when cells were treated with hydrogen peroxide (Fig. 5d). These findings 
were therefore in accord with the fact that toxicities of PARP inhibitors such as olaparib are linked to their ability 
to trap PARP1 on DNA by blocking its catalytic activity30.
The last clone without an assigned mutation driving resistance to olaparib (C1) may also carry one or more 
mutations in the non-exonic regions of the Parp1 gene, or epigenetic modifications altering Parp1 expression, 
since we could not detect the presence of PARP1 in protein extracts (Fig. 5a). Taken together, these results are 
consistent with a model in which olaparib resistance can arise either from loss of PARP1 or from its decreased 
ability to bind DNA (Fig. 5e).
Discussion
Various approaches have been described for systematic identification of genetic and chemo-genetic interactions. 
Until recently, this search has been largely conducted using approaches based on gene inactivation, either in 
arrayed or pooled assay formats. While these approaches have played crucial roles in determining gene-gene 
and gene-drug interactions, their limited power of resolution does not in general provide information regarding 
the functional protein domains relevant for the identified interaction. While transposon-based mutagenesis and 
dense CRISPR gRNA approaches have recently been shown to provide some information at the domain level, 
this approach is only applicable to loss-of-function mutations, and is biased towards C-terminal domains of pro-
teins34. In contrast, SNV based approaches can provide a higher level of resolution, and in many cases produce 
unanticipated results10,35–37. Lack of rapid and facile procedures to bridge the phenotype-to-genotype gap has 
until recently, however, precluded the use of these techniques on a high-throughput scale.
Figure 5. Missense mutations interfere with PARP1 DNA binding. (a) Olaparib resistant clones were assayed 
for the presence of PARP1 protein. A representative selection is shown, along with the Parp1 mutation carried 
by each clone: unknown indicates that no mutation could be automatically detected. Upon further, manual 
inspection, the mutations identified in brackets were discovered. More clones can be seen in Supplementary 
Figure 3a. (b) Location of missense mutations that do not lead to a loss of PARP1 protein are indicated on 
partial PARP1 structures of the ZN2 domain by itself (PDB code 3ODC) and the PARP1 protein except ZN2 
and the BRCT domain (PDB code 4DQY). (c) Clones carrying mutations that do not lead to loss of/reduction 
in PARP1 protein were assayed for the protein’s ability to bind a double-stranded DNA oligonucleotide. One 
experiment each was quantified. All blots can be viewed in Supplementary Figure 3b. (d) Cells with either wild 
type or mutant PARP1 protein were assayed for their ability to PARylate. Cells were either left untreated or 
treated with hydrogen peroxide (H2O2). Wild type cells were also treated with olaparib overnight before H2O2 
treatment. (e) Summary of olaparib resistant clone analysis. The inner circle shows the mutations that have been 
identified in every clone (dark yellow signifies mutations identified by manual inspection of the data). The outer 
circle shows the respective effect on PARP1 protein accounting for the mechanism of olaparib resistance.
www.nature.com/scientificreports/
7SCIenTIfIC REPORtS |  (2018) 8:6161  | DOI:10.1038/s41598-018-24400-4
The approach we have described allows the identification of SNVs driving drug resistance or resistance to 
essentially any selective growth condition in a systematic and unbiased way (other than any bias imposed by 
the mutagenic agent of choice). Importantly, this approach can equally be applied to yeast and to more complex 
eukaryotes, bringing the power of high-resolution haploid genetic screens to mammalian systems. It should how-
ever be noted that certain limitations of haploid genetics, such as the inability to formally distinguish between 
recessive and dominant alleles, will also apply to mammalian systems. While we acknowledge that we have carried 
out our screens with strong selectable cell-viability phenotypes, we envisage applicability in more complex sce-
narios, for example involving FACS-based selection or cell migration, motility or attachment assays. Highlighting 
this potential, our results show how, with no previous knowledge, Top1 and PARP1 would have been identified as 
the most likely targets for the drugs camptothecin and olaparib, respectively.
Toxicity to PARP inhibitors was initially linked to the involvement of PARP1 in the repair of single-strand 
DNA breaks38,39, but more recent data challenged this view40. The fact that loss of PARP1 drives resistance to 
PARP inhibitors in wild-type genetic backgrounds41 indeed suggests that inhibition of PARP1 catalytic activ-
ity — and not the accumulation of unrepaired DNA lesions — is the major effector of toxicity in such genetic 
backgrounds. Indeed, recent findings suggest that PARP1 trapping onto DNA, caused by inhibition of its catalytic 
activity, is the main cause of toxicity31. Our data further support this model, as all the suppressor clone variants 
which we identified that did not result in loss of PARP1 protein negatively affected its binding to DNA. Preventing 
PARP1 binding to DNA thus appears to be sufficient to circumvent the toxicity of PARP inhibitors, at least in 
homologous-recombination proficient cells; and the fact that we identified no mutants specifically defective in 
catalytic function reinforces the idea of trapped PARP1 as the main cytotoxic lesion for olaparib in wild-type 
mammalian cells. Further work in a diploid setting will be required to demonstrate whether the DNA-binding 
deficient alleles isolated are recessive, and that the PARP1-olaparib complex indeed acts as a dominant negative 
entity. This may not only be important for our understanding of how PARP inhibitors function but also for under-
standing mechanisms of intrinsic or evolved tumor resistance towards such clinical agents. In particular, it will 
be interesting to determine whether olaparib resistance in patients with BRCA1/2 mutant cancers can be driven 
by loss of PARP binding to DNA.
As exemplified by our analyses of Top1 and PARP1, the level of detail on critical functional domains and 
residues increases with the number of samples sequenced. Because of their genome size, screens based in mam-
malian systems require greater sequencing power than screens conducted in simpler organisms such as yeast. 
Moreover, as compared to yeasts, the more complex genome architecture in mammalian systems – where there is 
more intergenic DNA, a larger number of genes and an abundance of intronic sequences – increases the chances 
of isolating variants affecting protein levels, rather than protein function. One solution to bypass such issues 
will be to run two-tiered screens, initially using whole exome sequencing on a subset of suppressors in order to 
identify top gene hits driving resistance, and then using targeted exome sequencing to test the rest of the samples, 
either through analysis of various individual clones or bulk sequencing of the resistant population. In addition, 
we can envision alternative scenarios where a gene identified in an initial screen could be marked/tagged in a 
way to allow selection of mutations that affect protein function but not protein levels. This approach can also be 
combined with CRISPR-Cas9-mediated in vivo targeted mutagenesis, via a library of gRNAs directed towards the 
exonic regions of the gene (Pettitt et al., BioRxiv https://doi.org/10.1101/203224). We anticipate that such devel-
opments, along with expected further increases in sequencing throughput and associated cost reductions, will 
pave the way for hitherto unprecedented genetic analyses on comprehensive and systematic scales.
Methods
Yeast suppressors of camptothecin sensitivity. S. cerevisiae strains used were derived from W303. All 
gene deletions were introduced by using one-step gene disruption, and were confirmed by PCR and whole-ge-
nome sequencing. Full genotypes of strains are described in Supplementary Table 1. Standard growth conditions 
(1% yeast extract, 2% peptone, 2% glucose, 40 mg/l adenine) were used. Strains YFP1001 and YFP1073 were 
mutagenized by adding 4.5% ethyl methane sulfonate (EMS) to liquid cultures in logarithmic growth-phase, 
pelleted by centrifugation and then resuspended in 50 mM K-phosphate buffer for 10 minutes, followed by EMS 
inactivation with 1 volume of 10% sodium thiosulfate. Suppressors were obtained by plating each strain on 10 
YPD plates supplemented with 5 µg/ml of camptothecin (approximately 107 cells per plate). Resistant colonies 
were picked after 2–3 days of growth at 30 °C and isolated by streaking on YPD plates. Suppression was confirmed 
by retesting camptothecin sensitivity of the isolated strains. Confirmed suppressors were processed for DNA 
extraction shortly thereafter, in parallel with 2–3 colonies of the initial strain (Fig. 1a).
Mouse embryonic stem cell suppressors of olaparib sensitivity. Haploid mouse AN3-12 embryonic 
stem cells (mESCs)42,43 were used for all the experiments and were free from mycoplasma. Cells were grown 
in DMEM high glucose (Sigma) supplemented with glutamine, fetal bovine serum, streptomycin, penicillin, 
non-essential amino acids, sodium pyruvate, 2-mercaptoethanol and Leukemia inhibitory factor (LIF). All plates 
and flasks were gelatinized before cell seeding.
Cell sorting for DNA content was performed on mESCs by using a MoFlo flow sorter (Beckman Coulter) 
after staining with 15 μg/ml Hoechst 33342 (Invitrogen). The 1n peak was purified to enrich for haploid mESCs.
Mutagenesis with EMS was performed as described previously44 with the following adjustments: after cell 
sorting, haploid-enriched cells were grown in DMEM plus LIF for overnight EMS treatment. After EMS treat-
ment, cells were cultured for five passages in DMEM plus LIF and plated into 6-well plates at a density of 5 × 105 
cells per well. Cells were then treated with 6 μM of olaparib (AZD2281; Stratech Scientific Ltd.) for 6 days, supply-
ing new medium with olaparib daily. Cells were then grown for another four days without olaparib until mESC 
colonies could be isolated.
www.nature.com/scientificreports/
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Genomic DNA isolation. S. cerevisiae DNA isolation. Resistant colonies were inoculated in 1.8 ml of 
YPAD in 96-deep-well plates and grown for 48 hours. Pelleted cells were re-suspended in 500 μl of spheroplasting 
solution (1 M sorbitol, 0.1 M EDTA, 14 mM 2-mercaptoethanol, 1 mg/ml RNAse A, containing 5 mg/ml zymol-
yase) and incubated for 2 hours at 37 °C. Spheroplasts were subsequently re-suspended in 200 μl of lysis buffer 
(80% ATL buffer [QIAGEN #19076], 10% Proteinase K [QIAGEN #19133] and 10% RNAse A (10 mg/ml)] and 
incubated overnight (>16 h) at 56 °C. Genomic DNA was extracted from the resulting solution by using the 
Corbett X-Tractor Gene™ Robot with the following buffers: AL [QIAGEN #19075; diluted 50% with ethanol], 
DXW [QIAGEN #950154], DXF [QIAGEN #950163], and E [QIAGEN #950172] (Fig. 1a).
Mouse genomic DNA isolation. mESC clones were grown into 12-well plates. After trypsinising and resus-
pension in 200 μl PBS and 200 μl Buffer AL [QIAGEN], a proteinase K [QIAGEN, 20 μl] and RNase [QIAGEN, 
0.4 mg] digestion step was performed (incubating 10min at 56 °C). After adding 200 μl 96–100% ethanol the 
solutions were applied to QIAamp Mini spin columns following the QIAamp DNA Blood Mini Kit [QIAGEN] 
manufacturer’s protocol from there. Genomic DNA was eluted from the columns using 200 μl distilled water. A 
second elution was performed if the yield of the genomic DNA obtained was lower than 2 μg. Genomic DNA was 
stored at −20 °C short-term before sequencing (Fig. 1a).
Illumina library preparation and sequencing. Extracted DNA was tested for total volume, concen-
tration and total amount by using gel electrophoresis and the Quant-iTTM PicoGreen® dsDNA Assay Kit 
(ThermoFisher Scientific). Genomic DNA −500 µg (yeast) or 1–3 μg (mouse) – was fragmented to an average 
size of 100–400 bp (mouse) or 400–600 bp (yeast) by using a Covaris E210 or LE220 device (Covaris, Woburn, 
MA, USA), size-selected and subjected to DNA library creation via established Illumina paired-end protocols. 
Adaptor-ligated libraries were amplified and indexed via PCR. A portion of each library was used to create an 
equimolar pool comprising 45 indexed libraries for mouse samples, and 96 indexed libraries for yeast samples. 
For mouse whole-exome sequencing, pools were hybridized to SureSelect RNA baits (Mouse_all_exon; Agilent 
Technologies) (Fig. 1b).
Mouse libraries were sequenced at 15 samples per lane. Yeast libraries were sequenced at up to 96 samples per 
lane. Libraries were sequenced by using the HiSeq 2500 (Illumina) to generate 75 (mouse), or 100/125 (yeast) base 
paired-end reads according to the manufacturer’s recommendations.
Analysis of DNA sequence data to identify suppressor mutations. Alignment of DNA sequencing 
data. Sequencing reads were aligned to the appropriate reference genome using BWA aln (v0.5.9‐r16)45. The S. 
cerevisiae S288c assembly (R64-1-1) from the Saccharomyces Genome Database was obtained from the Ensembl 
genome browser. For mouse samples, the Mus musculus GRCm38 (mm10) was used. Where appropriate, all lanes 
from the same library were merged into a single BAM file, and PCR duplicates were marked by using Picard Tools 
(Picard version 1.128). The quality of the sequencing data post-alignment was assessed by using SAMtools stats 
and SAMtools flagstats (1.1+htslib−1.1), plot-bamstats, bamcheck and plot-bamcheck46 (Fig. 1c).
Variant calling, consequence annotation and filtering. SNVs and small insertions/deletions (INDELs) were 
identified using SAMtools mpileup (v.1.3)46, followed by BCFtools call (v.1.3)46. The following parameters were 
used for SAMtools mpileup: -g -t DP,AD -C50 -pm3 -F0.2 -d10000. Parameters for BCFtools call were: -vm -f 
GQ. All variants were annotated by using the Ensembl Variant Effect Predictor (VEP) v8247. To exclude low 
quality calls, variants were filtered by using VCFtools vcf-annotate (v.0.1.12b)48 with options −H −f +/q = 25/
SnpGap = 7/d = 5, and custom filters were written to exclude variants with a Genotype Quality (GQ) score of less 
than 10. In the case of whole-exome sequencing data, variants called outside of targeted regions were excluded. 
INDELs were left-aligned using BCFtools norm46.
Removal of background mutations. Variants that confer resistance are absent in the initial strain/cell line, as it 
is sensitive to the drug used. Bedtools intersect was therefore used to remove variants present in any S. cerevi-
siae control samples to eliminate variation of the background relative to the reference genome from the data-
set. Variant calls from mouse samples were filtered by removing all variants identified in sequencing data of 
three olaparib-sensitive AN3-12 clones using VCFtools vcf-isec48; INDELs were further verified by using the 
microassembly-based variant caller Scalpel49. To address the high false positive rate in INDEL variant calls, only 
the INDELs that were identified by both variant callers and have passed the filters were retained.
Variant prioritization. Variants were prioritized by their Ensembl VEP47 predicted consequence: we retained 
variants predicted to cause a frameshift, a premature stop codon, a missense mutation, a lost start/stop codon, 
a synonymous mutation, an in-frame insertion or deletion, and in the case of mouse data, those annotated to 
affect splice donor/acceptor bases. Genes were prioritized by ranking them by the number of distinct mutations 
identified in each gene.
Missense mutations identified in genes of interest were ranked by using predictions of PROVEAN/SIFT25,50–52 
and PredictProtein26. Scores below −2.5 for PROVEAN, above 50 for PredictProtein and below 0.05 for SIFT 
indicate likely deleterious consequences to protein function.
Analysis of olaparib resistant cell lines. Molecular modeling. Molecular models were generated by 
using PyMOL. Crystal structure data were obtained from RCSB Protein Data Bank (PDB). The codes for PARP1 
structures were 4DQY (human PARP1 without ZN2 or BRCT domain) and 3ODC (human PARP1 ZN2).
Antibodies for immunoblotting. Anti-PARP1 (Cell Signalling, 9542; 1:1000 in TBST 5% milk), anti-HDAC1 
(Abcam ab19845; 1:1000 in TBST 1% BSA), anti-PAR (Trevigen 4336-BPC-100, 1:1000 in PBST[0.05%Tween-20] 
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5% milk), and anti beta-actin (Cell Signaling #4970, 1:1000 in TBST 5% BSA) were incubated with western-blot 
membranes at 4 °C overnight with gentle rocking.
DNA binding assays. DNA binding of PARP1 was assayed by using a 26-bp palindromic DNA duplex 
(5′GCCTACCGGTTCGCGAACCGGTAGGC3′33) immobilized on Dynabeads™ M-280 Streptavidin 
(Invitrogen, 10 mg/ml). Individual incubations used 500 µg of protein extract and a buffer containing 10 mM 
HEPES (p.H. 7.4), MgCl2 (1.5 mM), 25% glycerol, KCl (200 mM), EDTA (0.2 mM), Roche protease inhibitor 
cocktail (0.7X), DTT (0.5 mM) and AEBSF (0.1 mM). Experiments were repeated at least twice.
PARylation assay. Cells were treated with 6 μM olaparib overnight, followed 1 mM H2O2 for 10 minutes in the 
dark, washed with ice-cold PBS and collected. Cells were lysed in Laemmli buffer (120 mM TrisHCl pH6.8, 4% 
SDS, 20% glycerol) and lysates were separated on 4–20% Tris-Glycine gradient gel followed by transfer onto 
PVDF membrane. Membranes were immunoblotted with the appropriate antibodies. Experiments were repeated 
at least twice.
Data availability. The datasets generated and/or analysed during the current study are available in 
the European Nucleotide Archive (ENA) under the accession code PRJEB2977 (yeast) and PRJEB13612 (mouse). 
Access codes for specific samples are detailed in Supplementary Table 2. Source data for Figs 2 and 3 are pro-
vided in Supplementary Table S2; source data for Figs 4 and 5 are provided in Supplementary Table S3 and 
Supplementary Figure S3.
Code availability. Custom code used to analyse sequencing data and to draw figures is available in the fol-
lowing repository: http://github.com/fabiopuddu/Herzog2018.
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